Related Experiment Video

Updated: Jul 13, 2026

Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles
09:15

Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles

Published on: November 10, 2017

Are statins effective for simultaneously treating dyslipidemias and hypertension?

Kwang Kon Koh1, Michael J Quon2, Myron A Waclawiw3

  • 1Vascular Medicine and Atherosclerosis Unit, Division of Cardiology, Gachon University, Gil Medical Center, 1198 Kuwol-dong, Namdong-gu, Incheon 405-760, South Korea.

Atherosclerosis
|July 31, 2007
PubMed

Insights

Statins, or 3-Hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors, modestly lower blood pressure in individuals with high blood pressure. This effect is observed regardless of cholesterol levels, offering potential dual benefits for cardiovascular health.

Area of Science:

  • Cardiology
  • Pharmacology
  • Hypertension Research

Background:

  • 3-Hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors (statins) are primary treatments for dyslipidemia, reducing cardiovascular events.
  • Statins possess pleiotropic effects, including anti-inflammatory actions and modulation of the renin-angiotensin system, suggesting potential benefits beyond lipid lowering.
  • Endothelial dysfunction and reduced arterial compliance are key factors in essential hypertension, raising the hypothesis that statins could treat both dyslipidemia and hypertension.

Purpose of the Study:

  • To investigate the efficacy of statin therapy in lowering blood pressure.
  • To clarify the controversy surrounding statins' effects on blood pressure due to methodological limitations in previous studies.

Main Methods:

  • Systematic review and meta-analysis of published clinical studies, including small trials and large randomized clinical trials.
  • Analysis of blood pressure changes in patient populations with varying baseline blood pressure and cholesterol levels.

Main Results:

  • Statins were found to exert a modest blood pressure-lowering effect.
  • This effect was significant in patients with high blood pressure but not in those with normal blood pressure.
  • The blood pressure-lowering effect of statins was independent of their lipid-lowering efficacy.

Conclusions:

  • Statin therapy demonstrates a modest benefit in reducing blood pressure, particularly in hypertensive individuals.
  • Statins may offer a dual therapeutic approach for patients with both dyslipidemia and hypertension.
  • Further research may explore the mechanisms and clinical implications of statins' antihypertensive effects.

Related Concept Videos

Lipid-Lowering Drugs: Statins and Miscellaneous Agents01:20

Lipid-Lowering Drugs: Statins and Miscellaneous Agents

Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...
Atherosclerosis III: Management01:26

Atherosclerosis III: Management

Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
Hypertension IV: Drug Therapy and Lifestyle Modifications01:28

Hypertension IV: Drug Therapy and Lifestyle Modifications

Multiple classes of antihypertensive medications are employed in treating hypertension. The most commonly recommended first-line treatments include:Thiazide Diuretics, such as chlorthalidone, increase sodium and water excretion from the body, reducing blood volume and blood pressure.Angiotensin-converting enzyme inhibitors, like lisinopril, block the conversion of angiotensin I to II, a potent vasoconstrictor lowering blood pressure.Angiotensin II Receptor Blockers (ARBs) prevent angiotensin II...
Peripheral Artery Disease III: Interprofessional Care01:27

Peripheral Artery Disease III: Interprofessional Care

Peripheral Artery Disease (PAD) is characterized by narrowed arteries that diminish blood flow to the extremities. Effective management of PAD requires an interprofessional approach involving various healthcare professionals. The critical aspects of interprofessional care for PAD patients focus on risk factor modification, drug therapy, exercise therapy, nutrition therapy, critical limb ischemia care, and interventional radiology and surgical procedures.The primary treatment goal for PAD...
Coronary Artery Disease V: Interprofessional Care01:27

Coronary Artery Disease V: Interprofessional Care

Interprofessional care for coronary artery disease includes pharmacological therapy and revascularization procedures.Pharmacological therapy for Coronary Artery Disease (CAD) aims to manage symptoms, prevent complications, and improve patient outcomes through various classes of medications:Antiplatelet Agents:Aspirin and Clopidogrel: These medications inhibit platelet aggregation, preventing blood clots, which is crucial for avoiding heart attacks and strokes. Doctors often prescribe these...
Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers01:26

Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers

Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...